Harnessing immune cells to leverage PARP inhibitors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39241744.
- Also identified by DOI 10.1016/j.cell.2024.07.058.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Tumor Microenvironment